Sol-Gel Technologies in brief
Sol-Gel Technologies is a listed company in the Biotechnology industry, based in Israel. Its last known market value was $99 M (July 2023); there is no current figure. In the year to December 2025 it had sales of $19 M and a net loss of $6 M. Its largest product and service lines by sales in 2025 were Sale of IP and license revenue (96%), Royalty (4%) and Service, Other (under 1%). By market, the largest shares of its 2025 sales came from USA (86%), Canada (9%) and Switzerland (4%). Its shares trade under the symbol 4SG.F (Frankfurt).
Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.
Sol-Gel Technologies timeline
- 2018
- 🔔· approximateInitial public offering on Frankfurt
Events of Sol-Gel Technologies from the company record. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.
Market cap history
World rank over time
Rank in Israel: #111 (Jan 2020) · #159 (Jan 2021) · #236 (Jan 2022) · #241 (Dec 2022) · #251 (Jul 2023)
Key ratios
- P/E ratio (TTM)
- n/m (loss)
- Price / sales (TTM)
- —
- Price / book
- —
- Free cash flow yield
- —
- Net margin (TTM)
- -31.6%
- Operating margin
- -38.9%
- Return on equity
- -26.9%
- Liabilities / assets
- 23.8%
- Revenue growth
- +68.0%
- R&D / revenue
- 117.6%
Financial history
| Fiscal year ending | Revenue | Growth | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | $19M | +68.0% | $-8M | $-6M | -31.6% |
| Dec 2024 | $12M | +644.5% | $-12M | $-11M | -91.7% |
| Dec 2023 | $2M | -60.1% | $-29M | $-27M | -1757.4% |
| Dec 2022 | $4M | -87.6% | $-16M | $-15M | -384.5% |
| Dec 2021 | $31M | +256.6% | $3M | $3M | 10.3% |
| Dec 2020 | $9M | -61.7% | $-30M | $-29M | -334.0% |
| Dec 2019 | $23M | +17515.4% | $-26M | $-25M | -107.5% |
| Dec 2018 | $0M | — | $-34M | $-32M | -24769.2% |
Cash flow, debt and per share
| Fiscal year ending | Operating cash flow | Capital spending | Free cash flow | EPS (diluted) | Dividend / share |
|---|---|---|---|---|---|
| Dec 2025 | $0M | $0M | $0M | $-2.19 | — |
| Dec 2024 | $-14M | $0M | $-14M | $-3.79 | — |
| Dec 2023 | $-18M | $0M | $-18M | $-10.01 | — |
| Dec 2022 | $-9M | $0M | $-10M | $-0.65 | — |
| Dec 2021 | $-8M | $0M | $-8M | $0.14 | — |
| Dec 2020 | $-25M | $0M | $-26M | $-1.30 | — |
| Dec 2019 | $-23M | $1M | $-23M | $-1.26 | — |
| Dec 2018 | $-23M | $1M | $-25M | $1.80 | — |
SEC filings
- Nov 12, 20266-KReport of foreign issuer
- Oct 6, 20266-KReport of foreign issuer
- Sep 30, 20266-KReport of foreign issuer
- Sep 17, 20266-KReport of foreign issuer
- Aug 20, 20266-KReport of foreign issuer
- May 28, 20266-KReport of foreign issuer
- Mar 24, 20266-KReport of foreign issuer
- Mar 19, 202620-FAnnual report (foreign issuer) · period to Dec 2025
- Dec 17, 20256-KReport of foreign issuer
- Nov 20, 20256-KReport of foreign issuer
- Nov 14, 20256-KReport of foreign issuer
- Sep 25, 20256-KReport of foreign issuer
Official filings of Sol-Gel Technologies with the US Securities and Exchange Commission.
Annual results
- Revenue
- $19 M
- Operating income
- $-8 M
- Net income
- $-6 M
For year ending December-2025 · source: SEC filing
Balance sheet
- Total assets
- $30 M
- Total liabilities
- $7 M
- Total equity
- $23 M
As of December-2025
Insider trading at Sol-Gel Technologies#
Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.
| Traded | Insider | Trade | Shares | Price | Value | Owned after | Filing |
|---|---|---|---|---|---|---|---|
| filed | Opaleye Management Inc.10% owner | Buyindirect | +1,493 | 65.95 | 98 Klocal | 540,000 | Form 4 |
| filed | Opaleye Management Inc.10% owner | Buyindirect | +1,631 | 66.80 | 109 Klocal | 538,507 | Form 4 |
| filed | Opaleye Management Inc.10% owner | Buyindirect | +3,097 | 68.71 | 213 Klocal | 536,876 | Form 4 |
| filed | Opaleye Management Inc.10% owner | Buyindirect | +3,390 | 68.74 | 233 Klocal | 533,308 | Form 4 |
| filed | Opaleye Management Inc.10% owner | Buyindirect | +471 | 69.37 | 33 Klocal | 533,779 | Form 4 |
| filed | Opaleye Management Inc.10% owner | Buyindirect | +918 | 69.52 | 64 Klocal | 527,818 | Form 4 |
| filed | Opaleye Management Inc.10% owner | Buyindirect | +2,100 | 68.98 | 145 Klocal | 529,918 | Form 4 |
| filed | Opaleye Management Inc.10% owner | Buyindirect | +900 | 68.95 | 62 Klocal | 526,900 | Form 4 |
Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals. This company files with the SEC as a foreign issuer; its insiders often report prices in the home currency, so amounts are as filed and not converted to dollars
Markets and events: Sol-Gel Technologies#
Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.
Fails to deliver
- : 172 shares at $68.66
- : 212 shares at $68.18
- : 59 shares at $68.19
- : 264 shares at $69.45
- : 413 shares at $68.30
Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables
Sol-Gel Technologies scorecard#
Passes 8 of the 14 checks that could be worked out: strongest in growth (4 of 6), weakest in profitability (2 of 5). Fiscal year 2025.
Valuationnot known
- –P/E below its peers' medianNo market cap.
- –Price to book below its peers' medianNo market cap.
- –Price to sales below its peers' medianNo market cap.
- –Free cash flow yield above 5%No market cap.
- –Earnings yield above the 10-year Treasury yieldNo market cap.
- –The price assumes slower growth than the last three years'No market cap.
Growth4 of 6
- ✓Revenue grew in the newest year68.0%Revenue up 68.0% in fiscal 2025.
- ✓Revenue up more than 5% a year over three years71.0%71.0% a year over the three years to fiscal 2025.
- ✓Faster growth over three years than its peers' median71.0%71.0% a year against Biotechnology's median of 12.9% (181 companies).
- ✗Earnings per share grew in the newest year-2.19 vs -3.79Diluted EPS -2.19 in fiscal 2025 against -3.79 the year before (report's currency).
- ✓Net income higher than five years earlier-$6 M-$6 M in fiscal 2025 against -$29 M in 2020.
- ✗Revenue rose in at least four of the last five years3 of 5Revenue rose in 3 of the five years to fiscal 2025.
Profitability2 of 5
- ✗Profitable in the newest year-$6 MNet income -$6 M in fiscal 2025.
- ✗Profitable in each of the last five years1 of 5Profitable in 1 of the five years to fiscal 2025.
- ✓Operating margin above its peers' median-38.9%-38.9% against Biotechnology's median of -60.5% (243 companies).
- ✗Return on equity above 15%-23.7%-23.7% in fiscal 2025.
- –Return on invested capital above 10%No return on invested capital on file.
- ✓Operating margin wider than three years earlier-38.9%-38.9% in fiscal 2025 against -418.6% in 2022.
Financial health1 of 2
- ✓Short-term assets cover short-term liabilities4.4×Current ratio 4.37 at the end of fiscal 2025.
- –Debt below equityDebt or equity is not on file (or equity is negative).
- –Net debt below three years of EBITDANet debt to EBITDA is not on file.
- –Operating income covers interest five timesInterest expense is not on file.
- ✗Cash from operations positive in each of the last three years1 of 3Positive in 1 of the three years to fiscal 2025.
- –Altman Z-score outside the distress zoneThe Z-score's figures are not all on file.
Shareholder returns1 of 1
- –Pays a dividendDividends are not on file.
- –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
- –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
- ✓Share count up no more than 2% in a year0.0%Diluted shares down 0.0% in fiscal 2025.
- –Dividends and buybacks above 3% of the market valueNo market cap.
- –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.
Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap (too old for the valuation checks, which need one at most 60 days old). A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work
Financial analysis, 2025#
Worked out from Sol-Gel Technologies's statements, beside the median of Biotechnology.
| Ratio | Trend | 2025 | Median of peers |
|---|---|---|---|
| Operating margin | -38.9% | -60.5% | |
| Net margin | -31.6% | -68.9% | |
| Return on equity | -23.7% | -61.0% | |
| Revenue growth, 3 years a year | 71.0% | 12.9% | |
| Revenue growth | 68.0% | 15.8% | |
| Free cash flow margin | 1.4% | -61.5% |
5of 7on the Piotroski tests of financial strength
- Net loss of $6 million, the 4th loss-making year in a row.
Sol-Gel Technologies: financial statements#
Income statement, balance sheet and cash-flow statement as reported, newest period first.
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | FY 2025to Dec 31, 2025 | FY 2024to Dec 31, 2024 | FY 2023to Dec 31, 2023 | FY 2022to Dec 31, 2022 | FY 2021to Dec 31, 2021 | FY 2020to Dec 31, 2020 | FY 2019to Dec 31, 2019 | FY 2018to Dec 31, 2018 | FY 2017to Dec 31, 2017 | FY 2016to Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | |||||||||||
| Revenue | 19+68.0%100% | 12+642%100% | 1.6−60.0%100% | 3.9−87.6%100% | 31+257%100% | 8.8−61.7%100% | 23+17655%100% | 0.1−25.9%100% | 0.2—100% | — | |
| Research and development | 23+28.1%118% | 18−24.4%154% | 24+85.6%1515% | 13−37.8%327% | 20−27.0%65.2% | 28−31.2%318% | 41+44.2%177% | 28+9.1%21819% | 26+51.6%14830% | 17—— | |
| Selling and marketing | 0−100%0.0% | 0.0−2.7%0.3% | 0.0−5.1%2.4% | 0.0r0.0+69.6%1.0% | 0.0−8.0%0.1% | 0.0−21.9%0.3% | 0.00.0%0.1% | 0.0−27.3%24.8% | 0.0—25.3% | — | |
| General and administrative | 4.2−27.4%21.5% | 5.7−22.0%49.8% | 7.4−1.0%474% | 7.4−11.9%192% | 8.5−23.8%27.0% | 11+34.0%126% | 8.3+50.4%36.1% | 5.5−8.3%4267% | 6.0+60.8%3449% | 3.7—— | |
| Operating income | −7.5—−38.9% | −12—−104% | −29—−1886% | −16−648%−418% | 3.0—9.5% | −30—−345% | −26—−113% | −34—−25985% | −32—−18180% | −21—— | |
| Income before tax | — | — | — | — | 3.2—10.3% | −29—−334% | −25—−107% | −32r−33—−24964% | −32—−18143% | — | |
| Income tax | 0—0.0% | 0—0.0% | 0—0.0% | — | 0—0.0% | 0−100%0.0% | 0.0—0.1% | — | — | — | |
| Net income including minority interests | −6.1—−31.6% | −11—−91.7% | −27—−1753% | −15−563%−384% | 3.2—10.3% | −29—−334% | −25—−107% | −32—−24964% | −32—−18143% | −21—— | |
| Net income attributable to shareholders | −6.1—−31.6% | −11—−91.7% | −27—−1753% | −15−563%−384% | 3.2—10.3% | −29—−334% | −25—−107% | −32—−24964% | −32—−18143% | −21—— | |
| Earnings per share, basic | -2.19—— | -3.79r-0.38—— | -10.01r-1.01—— | -0.65−564%— | 0.14—— | -1.30r1.30—— | -1.26r1.26−170%— | 1.80−64.1%— | 5.02+52.1%— | 3.30—— | |
| Earnings per share, diluted | -2.19—— | -3.79r-0.38—— | -10.01r-1.01—— | -0.65−564%— | 0.14—— | -1.30r1.30—— | -1.26r1.26−170%— | 1.80−64.1%— | 5.02+52.1%— | 3.30—— | |
| Shares, weighted average (basic) | 2.8+0.0%— | 2.8r28+2.8%— | 2.7r27−88.3%— | 23+0.3%— | 23+2.2%— | 23+15.6%— | 20—— | — | — | — | |
| Shares, weighted average (diluted) | 2.8+0.0%— | 2.8r28+2.8%— | 2.7r27−88.3%— | 23−1.9%— | 24+4.4%— | 23+15.6%— | 20+9.3%— | 18+184%— | 6.3+0.0%— | 6.3—— | |
| Balance sheet | |||||||||||
| Cash and cash equivalents | 11−43.4%36.9% | 19+159%54.4% | 7.5−39.6%16.6% | 12−38.0%26.7% | 20+182%29.0% | 7.1−24.3%12.0% | 9.4+76.8%15.4% | 5.3+6.0%7.6% | 5.0−28.2%32.8% | 7.0—63.7% | |
| Short-term investments | 13+193%43.3% | 4.4−78.4%12.3% | 20+136%45.2% | 8.7+408%18.6% | 1.7−92.1%2.5% | 22−47.1%36.6% | 41−27.7%66.8% | 57—81.3% | — | — | |
| Receivables | 2.0−45.3%6.6% | 3.6+854%10.0% | 0.4+508%0.8% | 0.1r7.9−99.5%0.1% | 13+507%18.9% | 2.2−47.7%3.6% | 4.1—6.7% | — | — | — | |
| Other current assets | 1.0−73.4%3.4% | 3.8+35.1%10.5% | 2.8+85.2%6.2% | 1.5r1.6+88.6%3.2% | 0.8−25.5%1.2% | 1.1−16.9%1.8% | 1.3−56.7%2.1% | 3.0+96.0%4.3% | 1.5r1.5+223%10.0% | 0.5—4.3% | |
| Current assets | 27−13.8%90.2% | 31−24.0%87.3% | 41−4.4%90.9% | 43−24.6%92.3% | 57+6.9%82.5% | 53−4.3%90.3% | 56−15.4%91.0% | 66+525%94.7% | 11+27.1%68.9% | 8.3—75.5% | |
| Property, plant and equipment | 0.1−30.7%0.5% | 0.2−53.5%0.6% | 0.4−34.2%1.0% | 0.7−37.2%1.4% | 1.1−42.2%1.5% | 1.8−21.5%3.1% | 2.3−11.1%3.8% | 2.6+12.5%3.7% | 2.3+190%15.1% | 0.8—7.3% | |
| Right-of-use (leased) assets | 1.0−28.0%3.4% | 1.4−17.1%4.0% | 1.7+96.5%3.8% | 0.9−41.6%1.9% | 1.5−20.8%2.2% | 1.9−7.1%3.2% | 2.0—3.3% | — | — | — | |
| Non-current assets | 2.9−35.3%9.8% | 4.6+10.5%12.7% | 4.1+15.3%9.1% | 3.6−70.4%7.7% | 12+110%17.5% | 5.8+4.5%9.7% | 5.5+48.6%9.0% | 3.7−22.2%5.3% | 4.8+77.3%31.1% | 2.7—24.5% | |
| Total assets | 30−16.5%100% | 36−20.8%100% | 45−2.9%100% | 47−32.6%100% | 69+17.0%100% | 59−3.5%100% | 61−12.0%100% | 70+355%100% | 15+39.4%100% | 11—100% | |
| Accounts payable | 0.7−41.9%2.5% | 1.3+721%3.5% | 0.2−38.6%0.3% | 0.3−67.2%0.5% | 0.8−36.3%1.1% | 1.2−29.6%2.0% | 1.7−41.5%2.8% | 2.9+448%4.2% | 0.5−19.9%3.5% | 0.7—6.1% | |
| Current liabilities | 6.2+16.8%20.6% | 5.3+16.9%14.7% | 4.5+35.8%10.0% | 3.3−71.5%7.1% | 12+96.0%16.9% | 6.0−8.3%10.1% | 6.5+32.9%10.6% | 4.9−92.7%7.0% | 67+61.4%439% | 42—379% | |
| Lease liabilities (non-current) | 0.5−43.5%1.7% | 0.9−27.2%2.4% | 1.2+2133%2.7% | 0.1−93.3%0.1% | 0.8−37.6%1.2% | 1.3−5.4%2.2% | 1.4—2.2% | — | — | — | |
| Non-current liabilities | 0.9−45.4%3.1% | 1.7−19.3%4.8% | 2.1+95.3%4.7% | 1.1−42.9%2.3% | 1.9−19.0%2.8% | 2.3+0.7%4.0% | 2.3+165%3.8% | 0.9+8.4%1.3% | 0.8+16.7%5.3% | 0.7—6.3% | |
| Total liabilities | 7.1+1.6%23.8% | 7.0+5.3%19.5% | 6.6+50.5%14.7% | 4.4−67.5%9.5% | 14+63.6%19.6% | 8.3−5.9%14.0% | 8.8+53.1%14.4% | 5.8−91.5%8.3% | 68+60.7%444% | 42—385% | |
| Retained earnings | −237—−792% | −231—−644% | −220—−486% | −193—−414% | −178—−257% | −181—−307% | −152—−248% | −127—−183% | −95—−622% | −64—−580% | |
| Shareholders' equity | 23−20.9%76.2% | 29−25.3%80.5% | 39−8.5%85.3% | 42−24.1%90.5% | 56+9.3%80.4% | 51−3.1%86.0% | 52−17.9%85.6% | 64—91.7% | −53—−344% | −31—−285% | |
| Total liabilities and equity | 30−16.5%100% | 36−20.8%100% | 45−2.9%100% | 47−32.6%100% | 69+17.0%100% | 59−3.5%100% | 61−12.0%100% | 70+355%100% | 15+39.4%100% | 11—100% | |
| Shares outstanding | 2.8−0.0%— | 2.8r28−90.0%— | 28+20.4%— | 23+0.0%— | 23+0.5%— | 23+12.7%— | 20+7.7%— | 19+201%— | 6.3+0.0%— | 6.3—— | |
| Cash-flow statement | |||||||||||
| Depreciation and amortization | 0.1−53.2%0.6% | 0.2−31.9%2.0% | 0.3−39.1%22.0% | 0.6−36.1%14.5% | 0.9−7.0%2.8% | 0.9+6.7%10.8% | 0.9+16.4%3.9% | 0.8+61.8%591% | 0.5+31.2%271% | 0.4—— | |
| Share-based compensation | 0.1−89.6%0.4% | 0.8−57.7%6.8% | 1.9+21.7%120% | 1.5+122%39.3% | 0.7−43.5%2.2% | 1.2−52.3%13.9% | 2.6−45.2%11.1% | 4.7+17.1%3608% | 4.0+317%2284% | 1.0—— | |
| Cash from operating activities | 0.3—1.7% | −14—−120% | −18—−1141% | −9.5—−244% | −7.7—−24.6% | −25—−288% | −23—−98.2% | −23—−18191% | −24—−13844% | −18—— | |
| Capital expenditure | −0.0—−0.2% | −0.0—−0.0% | −0.1—−8.6% | −0.2—−4.4% | −0.1—−0.5% | −0.4—−5.1% | −0.6—−2.6% | −1.1—−816% | −1.9—−1106% | −0.4—— | |
| Cash from investing activities | −8.6−132%−44.3% | 27—231% | −9.7−673%−627% | 1.7−91.5%43.8% | 20—63.5% | −2.7−117%−30.7% | 16—70.0% | −55—−42430% | −5.9—−3413% | −0.4—— | |
| Cash from financing activities | 0.0—0.0% | 0−100%0.0% | 22+145300%1403% | 0.0−98.2%0.4% | 0.8−96.8%2.7% | 26+149%302% | 11−86.5%46.3% | 79+181%61100% | 28+40.0%16092% | 20—— | |
| Exchange-rate effect on cash | — | — | — | — | −0.1—−0.2% | −0.0—−0.1% | −0.1−247%−0.2% | 0.0−32.0%26.4% | 0.1—28.7% | −0.0—— | |
| Change in cash | −8.4−166%−43.5% | 13—111% | −5.7—−369% | −7.6−159%−197% | 13—41.5% | −1.5−136%−17.0% | 4.1+528%17.8% | 0.7—505% | −2.0−279%−1136% | 1.1—— | |
| Report | 20-F | 20-F | 20-F | 20-F | 20-F | 20-F | 20-F/A | 20-F | 20-F | 20-F | |
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.
Source: SEC EDGAR filings (XBRL) · as of Dec 31, 2025. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative
What Sol-Gel Technologies sells: revenue by product line, fiscal 2025#
As the company reports it, in US dollars, with each line's share of total revenue and the change on fiscal 2024. Lines can overlap (a total and its parts), so they are not added up.
Products and services
- Sale of IP and license revenue$19 M96%+90%
- Royalty$1 M3.6%-56%
- Service, Other$0 M0.4%-38%
Countries and regions
- 🇺🇸 USA$17 M86%—
- 🇨🇦 Canada$2 M8.7%+147%
- 🇨🇭 Switzerland$1 M3.7%-52%
- Other$0 M1.4%-59%
- 🇨🇳 China$0 M0.1%-99%
Source: SEC annual report (XBRL data) · as of Dec 31, 2025
Where Sol-Gel Technologies operates: 5 countries#
Countries where the company has its headquarters, an office, subsidiaries, a branch or reported revenue.
| Country | Presence | Revenue there |
|---|---|---|
| 🇮🇱 Israel | Headquarters | — |
| 🇺🇸 USA | $17 M86% | |
| 🇨🇦 Canada | $2 M8.7% | |
| 🇨🇭 Switzerland | $1 M3.7% | |
| 🇨🇳 China | $0 M0.1% |
Source: GLEIF legal-entity register, SEC Exhibit 21 and annual reports, office addresses on file. A country without subsidiaries or offices on record is not listed even if the company sells there. How presence is decided
How Sol-Gel Technologies compares in Biotechnology
- Revenue$19 M · higher than 50% of 647
- Net margin-31.6% · higher than 57% of 408
- Revenue growth68.0% · higher than 79% of 438
Peer comparison · Biotechnology
| Company | Market cap | P/E | Net margin | Rev. growth |
|---|---|---|---|---|
| Sol-Gel Technologies🇮🇱 | $99 M | — | -31.6% | +68.0% |
| Novo Nordisk A/S🇩🇰 | $203.2 B | 13.1× | 33.1% | +10.8% |
| Vertex Pharmaceuticals Incorporated🇺🇸 | $134.3 B | 33.8× | 30.7% | +8.9% |
| Moderna, Inc.🇺🇸 | $90.1 B | — | -110.5% | -39.9% |
| Regeneron Pharmaceuticals, Inc.🇺🇸 | $84.1 B | 17.5× | 28.5% | +1.0% |
| Argenx SE🇳🇱 | $52.8 B | 40.9× | 31.1% | +89.9% |
| CSL Limited🇦🇺 | $51.6 B | — | -16.4% | — |
| Samsung Biologics Co., Ltd.🇰🇷 | $51.5 B | 40.5× | 39.2% | — |
| UCB SA🇧🇪 | $48.6 B | 26.3× | 20.1% | +31.1% |
P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.
Questions, comparisons and similar companies#
Questions people ask
Compare head to head
Similar companies by size and industry
- Novo Nordisk A/S$203.2 B
- Vertex Pharmaceuticals Incorporated$134.3 B
- Moderna, Inc.$90.1 B
- Regeneron Pharmaceuticals, Inc.$84.1 B
- Argenx SE$52.8 B
- CSL Limited$51.6 B
Sources and freshness
- Market cap:
- Jul 30, 2023 (last known)
- Annual results:
- For year ending December-2025
- Balance sheet:
- As of December-2025
- Profile updated:
- Nov 16, 2026
Figures from SEC filing, value.today research; financial statements from SEC filings.
How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.
Work at Sol-Gel Technologies? Verify and update this profile — free
Show Sol-Gel Technologies's ranking or a chart on your website Get the badge
The badge updates itself as the ranking changes.